Teledol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Teledol

Quick Facts

Property Description
Active ingredient Ketorolac tromethamine
Form Tablets, Solution for injection, Ophthalmic solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Pain relief (Analgesia) and Inflammation reduction
Origin Synthetic compound

What Type of Medicine is Teledol?

Teledol is a pharmaceutical product containing the potent analgesic substance Ketorolac tromethamine, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification is officially recognized by authoritative bodies, placing it within the pyrrolo-pyrrole chemical group of compounds. As a synthetic compound, Ketorolac is functionally distinct from opioid analgesics, targeting peripheral pain responses rather than the central nervous system. This pharmacological identity immediately clarifies that the medicine's primary role is anchored in mitigating discomfort and swelling, a characteristic feature that is supported by clinical experience.


Composition, Forms, and General Purpose

The medication is a single-ingredient product, utilizing Ketorolac tromethamine as the sole active compound to mediate its therapeutic effects. Teledol is manufactured in multiple dosage forms, allowing for diverse routes of administration, including tablets for oral use, a solution for injection for parenteral delivery, and an ophthalmic solution for topical application. The overarching therapeutic purpose of the compound is to provide powerful analgesia and to mitigate the symptoms of inflammation. Its mechanism involves inhibiting the body's prostaglandin synthesis pathway, which fundamentally interrupts the local chemical processes that initiate and sustain pain signals. This action contributes significantly to the relief of acute pain and associated inflammation.

What side effects are possible with Teledol?

Teledol is a potent non-steroidal anti-inflammatory drug (NSAID) and is associated with serious, potentially fatal, risks that are documented in regulatory warnings. Its use is strictly limited to short-term therapy, typically no more than five days in total, due to the increased risk of adverse events with prolonged use.

Serious and Clinically Significant Risks

The primary serious risks involve the gastrointestinal and cardiovascular systems:

  • Gastrointestinal Risk: The medication can cause peptic ulcers, gastrointestinal bleeding, and/or perforation of the stomach or intestines, which may be fatal. These severe events can occur at any time without warning symptoms. Elderly patients and those with a prior history of gastrointestinal bleeding or ulcers are at greater risk.
  • Cardiovascular Thrombotic Events: Teledol may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can also be fatal. This risk may be heightened with longer duration of use and in patients with underlying cardiovascular disease or risk factors.

Additional severe reactions include acute renal failure, serious skin reactions (such as Stevens-Johnson Syndrome), and anaphylactic reactions.

Common Adverse Reactions

Adverse reactions reported in 1% to 10% of patients include gastrointestinal experiences (e.g., abdominal pain, nausea, dyspepsia, diarrhea, flatulence) and nervous system effects (e.g., headache, dizziness, drowsiness), as well as edema and injection site pain.

Contraindications and Restrictions

Teledol is contraindicated (should not be used) in patients with active or history of peptic ulcer disease or GI bleeding, advanced renal impairment, a high risk of bleeding, suspected or confirmed cerebrovascular bleeding, and for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. It is also not recommended in late pregnancy due to potential harm to the unborn baby and interference with labor.

Overdose and Emergency Response

Suspected overdosage with Teledol requires immediate medical attention and hospital management. This mandate is driven by the potential for severe or life-threatening systemic toxicity documented in official regulatory labeling.

Official Manifestations and Severe Outcomes

Acute overexposure is officially documented to present with gastrointestinal symptoms, including epigastric pain, nausea, and vomiting. Central nervous system effects such as lethargy and drowsiness are also reported. While initial symptoms may be reversible, severe consequences can occur.

Officially documented severe outcomes include acute renal failure, hepatic dysfunction, and life-threatening events such as severe gastrointestinal hemorrhage, seizures, and coma. Metabolic acidosis has also been reported following intentional overdose.

Management and High-Risk Considerations

Management is strictly based on symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known. Procedures such as gastric lavage and administration of activated charcoal may be considered, but hemodialysis is officially noted as ineffective in clearing the drug. Close clinical monitoring is required. Regulatory information indicates that elderly patients and those with underlying impaired renal function may be at increased risk for the most severe outcomes.

Therapeutic Uses of Teledol

What Teledol Treats: Main Uses and Benefits

Teledol is an NSAID used for symptoms that require high-level relief, primarily for the short-term relief of moderate-to-severe acute pain. It is often used in the context of post-surgical recovery or acute injury, where the discomfort creates noticeable physiological strain. Its application is relevant for acute, time-limited pain.


This medication is commonly used to help address symptom clusters that may become intense or disruptive, such as the severe discomfort experienced after operations, during acute episodes of severe headache, or pain associated with localized swelling and inflammation. It is relevant in conditions where symptoms are linked to inflammatory or irritative states, assisting with conditions like acute musculoskeletal issues, postoperative discomfort, and severe menstrual pain (dysmenorrhea).

When used topically, the medication is applied across domains where additional symptomatic support is needed for the eye, relevant for easing localized symptoms of ocular pain and burning following surgery or the symptoms associated with seasonal ocular irritation. This use may help provide supportive relief when symptoms interfere with routine activities.

“This symptomatic relief generally supports patients by offering assistance in maintaining comfort and stability during periods of heightened symptoms.”


Quick Fact: Relief for High-Intensity Symptoms

Property Description
Relevant Scope Acute, moderate-to-severe pain
Symptom Coverage Pain, swelling, inflammation, ocular discomfort
Typical Context Postoperative care, acute injury, emergency settings
Benefit Statement Contributes to easing the overall symptom load

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Teledol?

This section outlines the official population eligibility and non-eligibility for Teledol, as defined by authoritative governmental regulatory documents.


Absolute Contraindications

Teledol is strictly contraindicated (must not be used) in several patient populations. This prohibition applies to patients with active peptic ulcer disease, a history of gastrointestinal bleeding or perforation, or any condition posing a high risk of bleeding (including cerebrovascular bleeding). It is also prohibited for patients with known hypersensitivity to Ketorolac or allergic reactions to aspirin or other NSAIDs. Use is strictly forbidden in patients with advanced renal impairment.


Age and Physiological Restrictions

Safety and efficacy have not been established for patients younger than 17 years. The oral formulation is not indicated for pediatric use. Older adults (65 years and older) require a lower, adjusted maximum dose due to higher risk of serious adverse events.

Use is avoided/contraindicated in breastfeeding women and from 30 weeks gestation (third trimester of pregnancy). The medicine is also contraindicated for treating pain following Coronary Artery Bypass Graft (CABG) surgery or during labor and delivery.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Teledol (Ketorolac tromethamine) has officially documented interaction patterns that necessitate strict regulatory constraints on co-administration with specific medications and substances.

Formal Prohibited Combinations

The following combinations are formally contraindicated due to the high risk of serious adverse outcomes:

  • Other NSAIDs, including Aspirin: Co-administration is prohibited due to the cumulative pharmacodynamic risk of gastrointestinal bleeding and ulceration.
  • Anticoagulants (e.g., Warfarin, Heparin) and Oxpentifylline (Pentoxifylline): These are prohibited due to the significantly increased and potentially severe risk of hemorrhage and bleeding.
  • Probenecid: Prohibited because it substantially decreases the renal clearance of Ketorolac, leading to high systemic exposure and increased plasma concentrations (AUC up to threefold).

Exposure and Pharmacodynamic Effects

Interactions with other medicines may result in exposure modifications or additive pharmacodynamic effects:

  • Reduced Clearance: Teledol may reduce the renal clearance of Lithium and Methotrexate, which can increase the plasma concentrations and risk of toxicity for those medicines.
  • Blunted Therapeutic Effect: Teledol may diminish the antihypertensive effect of ACE Inhibitors and ARBs, and the natriuretic effect of Diuretics.
  • Additive Risk: Co-administration with SSRIs or Corticosteroids is associated with an increased risk of gastrointestinal bleeding.

Administration Constraints

The total combined duration of use for all systemic formulations of Ketorolac tromethamine (oral, injectable, nasal) must not exceed 5 days to mitigate cumulative risk.

Mechanism of Action

How Teledol Works

Teledol (Ketorolac tromethamine) acts by engaging a key enzyme-mediated signaling pathway to alter chemical signaling within the inflammatory and nociceptive pathways. Its mechanism is defined by targeted interference with the body’s own chemical synthesis processes.


The primary molecular action is the non-selective inhibition of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By competitively blocking the active sites of these enzymes, Teledol suppresses the conversion of arachidonic acid into prostanoids like PGE2 . This inhibition modifies an early molecular step that shapes downstream physiological outcomes.

The subsequent reduction in PGE2 levels directly reduces the chemical sensitization of peripheral nociceptors at the site of tissue damage. This attenuates signaling within the peripheral nervous system, which influences the physiological mechanism of nociception. Furthermore, the mechanistic cascade affects local vascular dynamics, limiting the chemical signaling that drives vasodilation and increased vascular permeability. This physical restriction of the fluid-shift process results in altered vascular dynamics, affecting localized fluid accumulation.

Dosage and Administration Information

How to Use Teledol

Teledol, containing ketorolac tromethamine, is approved for systemic administration via oral tablets, intravenous (IV) injection, and intramuscular (IM) injection. A topical ophthalmic solution is also authorized for localized use.


The overarching principle of systemic use is that the total combined duration of all administration routes (oral, IV, and IM) must not exceed 5 days in adults. The medication is typically administered every 4 to 6 hours as needed for pain management.


Administration Sequence and Dosing

Parenteral injection is generally initiated for acute pain management. The oral tablet (10 mg strength) is designated only for continuation therapy, and is not approved for starting treatment. This establishes a required sequential pattern of use.

Dose adjustments are required for specific populations. Patients who are older than 65 years, weigh less than 50 kg, or have renal impairment must receive a reduced maximum parenteral dose, capped at 60 mg/day, which is half the standard adult maximum. Furthermore, proper technique requires that the intravenous bolus dose be administered slowly, over no less than 15 seconds.

Recent Clinical Evidence

Research evidence / Overview of studies

This section summarizes the published research that has evaluated the drug and its possible biological activity.


Research into Activity: Focus on Biological Pathways

Research has explored the hypothesis of activity involving specific biological pathways. Studies suggest that Teledol is a non-selective NSAID that inhibits cyclooxygenase (COX) enzymes, particularly COX-2, which is associated with the production of inflammatory and pain-mediating prostaglandins. The focus of research has been on the relationship between this activity and observations of pain or inflammation. Laboratory studies have investigated the potential for the compound to selectively influence inflammatory markers, which is a key area of study related to joint issues.


Clinical Efficacy: Findings from Human Trials

Studies have examined the potential for improvement in joint function and pain management. Findings from meta-analyses reported that studies including participants who took the drug found lower pain scores compared to placebo in some measurements. The effect size varied across the trials included in the analysis.

  • Pain Reduction: In studies of acute postoperative pain, Teledol significantly reduced pain compared to controls at 0–6 hours. Some studies found the reduction was clinically meaningful, exceeding the Minimal Clinically Important Difference (MCID) on the Visual Analog Scale (VAS) during this early period.
  • Functional Measures: Another set of randomized controlled trials (RCTs) reported that participants who received the drug showed a statistically significant reduction in opioid consumption and length of hospital stay compared to control groups, which can relate to functional recovery after surgery.

Safety Profile: Summary of Reported Side Effects

Research indicates the most commonly reported side effects were gastrointestinal discomfort and mild headache. Reported side effects generally did not result in study discontinuation. Studies noted that the drug's use was explored with additional attention for people with kidney impairment, as observed in some trials. Serious adverse events were infrequent in the reported trials.

Key Studies & References

  1. Multicenter Randomized Controlled Trial on Opioid-Sparing Effects of a Perioperative NSAID in Orthopedic Surgery
  2. NICE Guideline NG193: Pain Management in Adults

Frequently Asked Questions (FAQ)

Common questions about Teledol (FAQ)


Q: What is the purpose of the warning box (Black Box Warning) sometimes seen with medicines like Teledol?

Regulatory documents, such as the official labeling, include a Boxed Warning to clearly highlight serious and potentially life-threatening risks associated with the medicine. These warnings focus on the potential for severe gastrointestinal bleeding, ulcers, and cardiovascular thrombotic events. This regulatory tool also serves to strictly limit systemic use to a maximum of five days to mitigate these cumulative risks.


Q: How quickly can a person expect Teledol to start working?

Official product information, including pharmacokinetic data, indicates that the time required to reach the maximum concentration of the medicine in the body (Tmax) is generally between 30 to 60 minutes for both the injectable and oral forms. This period indicates when the maximum concentration is reached in the body, which is a factor influencing the onset of the expected effect.


Q: How long does the effect of one dose of Teledol usually last?

The official dosing instructions specify a fixed interval of administration, usually every 4 to 6 hours. This interval is set because it is based on the medicine's short-term duration of analgesic action in the body, which is also related to its elimination half-life.


Q: Does Teledol cause dependency or addiction issues as described in official documents?

Teledol (ketorolac tromethamine) is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not classified as a controlled substance. Unlike opioid analgesics, the regulatory labeling does not contain warnings or information regarding physical dependence or abuse potential.


Q: Is Teledol safe for older adults (seniors) to use?

Official labeling addresses the use of Teledol in older adults (65 years and older) by noting they are at a higher risk for serious side effects. Therefore, regulatory guidelines require that this population receive a reduced maximum daily dose of the medicine.


Q: What is the maximum amount of time Teledol has been studied for continuous use?

To mitigate the cumulative risk of serious side effects, regulatory documents strictly limit the total combined duration of systemic use (oral, IV, and IM) to a maximum of five days. Prolonged use beyond this short-term limit is associated with an increased risk of adverse cardiovascular and gastrointestinal events.


Q: Why is Teledol prescribed for several different conditions?

Teledol is officially indicated for the short-term management of moderately severe acute pain. This broad use is consistent with its primary function as an NSAID, which works by inhibiting the production of pain and inflammation-mediating chemicals in the body.


Q: What does 'contraindicated' mean in relation to Teledol?

In official regulatory documents, a medicine being 'contraindicated' means that its use is prohibited under specific conditions or for certain patient populations. This prohibition exists because using the drug under these circumstances could cause serious or life-threatening harm, such as in patients with active ulcers or advanced kidney disease.


Q: Why are there different strengths of Teledol tablets?

Different strengths are available to support the specific needs of the approved treatment regimen. This allows healthcare providers to properly manage dosing, which includes the required use of a 10 mg tablet specifically for short-term continuation therapy after an initial injectable dose.


Q: What should be done if I experience a rare or unexpected side effect from Teledol?

Official patient information indicates that patients are advised to contact a healthcare provider promptly if any side effect is experienced, particularly if it is unexpected, severe, or concerning. Regulatory guidelines also encourage reporting serious adverse reactions to the relevant authority.


Q: Is it possible for food to affect how Teledol works?

Official information for the oral tablet form indicates that taking the medicine with a high-fat meal may result in a delay in the time it takes for the drug to reach its peak concentration in the body. However, the overall amount of the medicine absorbed is typically unchanged.


Q: Are there any specific vitamins or supplements that are known to interact with Teledol?

Official drug interaction sections list known interactions with certain prescription medications and substances. Since Teledol affects bleeding risk, any non-drug product that also affects blood clotting or kidney function may require caution and is part of the established interaction profile.


Q: Does Teledol require special handling or prescription forms?

Teledol (ketorolac tromethamine) is a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not classified as a controlled substance under current regulatory frameworks, meaning it does not require the special handling or prescription forms associated with scheduled narcotic drugs.


Q: Does taking Teledol at the same time every day change its efficacy?

Official dosing instructions specify a fixed interval of administration (e.g., every 4 to 6 hours) rather than a specific time of day. This consistent timing is intended to support the maintenance of effective levels of the medicine in the bloodstream for short-term pain relief.


Q: How can I tell if Teledol is working for me?

The medicine is indicated for the short-term management of moderately severe acute pain. The expected clinical outcome indicating it is working would be a reduction in the intensity of the pain and inflammation symptoms for which it was prescribed.


Q: Does Teledol have an effect on a person's mood or emotional state?

Official documents list potential nervous system adverse reactions. These have included feelings of nervousness, difficulty concentrating, and, in rare instances, euphoria, which relates to a person's emotional state.


Q: What kind of monitoring is typically required while taking Teledol?

Due to the risk of severe gastrointestinal bleeding and kidney impairment, regulatory documents emphasize the need for monitoring. This typically includes monitoring for signs of bleeding, changes in kidney function, and signs of fluid retention during the short course of treatment.


Q: Is it a common practice to gradually stop taking Teledol?

Given that the maximum approved duration for systemic use is strictly limited to five days, regulatory documents do not specify a dose tapering or gradual reduction when stopping the medicine. Use is typically discontinued after the short-term course is complete.


Q: What do official sources say about taking Teledol with alcohol?

Official warnings advise that consuming alcohol while taking Teledol can increase the risk of serious side effects. This combination is specifically cautioned against because of the heightened potential for severe stomach bleeding and ulcers.


Q: Can Teledol be taken if a person has liver disease?

Official warnings advise that the use of Teledol may result in elevations in liver tests. It is contraindicated in patients with established severe liver failure, and regulatory guidance states that the medicine's use is discontinued if signs or symptoms of liver disease develop.


Q: What does the term 'half-life' mean in relation to Teledol?

The 'half-life' is a regulatory measure used in pharmacokinetics that describes the time it takes for the concentration of the medicine in the body's bloodstream to be reduced by half. The half-life of Teledol’s active substance is approximately 4 to 6 hours in healthy adults.


Q: What are the differences between generic and brand-name Teledol?

Regulatory agencies require that a generic version of a medicine must contain the same active ingredient and be bioequivalent to the brand-name version. This means the generic product is expected to work the same way and provide the same clinical effect as the brand name.


Q: Is there a patient information leaflet available for Teledol?

Yes. Because Teledol carries serious safety warnings, a specific regulatory document called a Medication Guide is required to be provided to patients. This document outlines the medicine's approved uses and risks in clear, patient-friendly language.


Q: What happens in the body when Teledol starts to wear off?

When the medicine begins to wear off, the body's natural processes of metabolism and elimination are removing the drug’s active substance from the bloodstream. This process is primarily conducted through the liver and excretion via the kidneys.

How should Teledol be stored and disposed of?

How to Store and Dispose of Teledol?

The storage of Teledol (ketorolac tromethamine) is mandated to protect its stability, requiring storage at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The regulatory labeling specifies that the oral tablets must be protected from moisture and kept in the original container with the cap tightly closed.

Storage and Handling Constraints

Dosage Form Primary Environmental Protection
Tablets Protect from moisture
Solution for Injection Protect from light; Do not freeze

All Teledol products must be stored out of the sight and reach of children. For disposal of unused or expired medicine, the official protocol for non-controlled substances must be followed. This involves using a drug take-back program or securely disposing of the product in the household trash, explicitly avoiding disposal in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Teledol found in:

A-Z Index: